B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)

Abstract
No abstract available

This publication has 0 references indexed in Scilit: